https://www.biospace.com/article/releases/mosaic-immunoengineering-inc-provides-an-overview-of-development-plans-for-advancing-its-lead-immuno-oncology-product-candidate-mi-o-101/

"Immunotherapy has become the standard of care for many cancers and yet there remains a large and growing market opportunity to make existing immuno-oncology and other standard cancer treatments more effective in a greater percentage of patients. The collective data generated to date with our immuno-oncology platform support its potential for the treatment of multiple cancer types in combination with standard of care therapies including checkpoint inhibitors such as PD-1, radiation and chemotherapy," said Steven King, president and chief executive officer of Mosaic. "The potential of veterinary oncology applications is complimentary to the development of MI-O-101 in humans and could represent an early market opportunity that we are continuing to evaluate.

We look forward to updating our stockholders as we advance the program through new data publications, upcoming presentations and new guidance resulting from our regulatory discussions."

have we received any updates